Beyond Air, Inc. (XAIR): Price and Financial Metrics
XAIR Price/Volume Stats
| Current price | $5.34 | 52-week high | $11.76 |
| Prev. close | $5.30 | 52-week low | $4.90 |
| Day low | $5.20 | Volume | 296,700 |
| Day high | $5.39 | Avg. volume | 317,143 |
| 50-day MA | $5.91 | Dividend yield | N/A |
| 200-day MA | $6.71 | Market Cap | 160.69M |
XAIR Stock Price Chart Interactive Chart >
Beyond Air, Inc. (XAIR) Company Bio
Beyond Air, Inc. operates as a medical device and biopharmaceutical company. The Company focuses on the discovery and development of a nitric oxide formulation and delivery systems to treat various respiratory diseases. Beyond Air serves patients and customers in the United States and Israel.
Latest XAIR News From Around the Web
Below are the latest news stories about BEYOND AIR INC that investors may wish to consider to help them evaluate XAIR as an investment opportunity.
Beyond Air® Schedules Fiscal Year End 2023 Financial Results Conference Call and WebcastCall scheduled for Thursday, June 22nd at 4:30 pm Eastern TimeGARDEN CITY, N.Y., May 16, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid t |
Beyond Cancer™ Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the American Association for Cancer Research (AACR) 2023 Annual MeetingSingle and repeat dosing of UNO improves outcomes compared to checkpoint inhibitor monotherapy in the aggressive 4T1 breast cancer model mPD-L1 upregulation following UNO treatment helps to elucidate the mechanism for the previously reported sensitization of tumors to immune checkpoint blockade Phase 1 first-in-human study ongoing and expanded to multiple centers GARDEN CITY, N.Y. and HAMILTON, Bermuda, April 19, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NAS |
Beyond Air® Appoints Jeff Myers, M.D. Ph.D. as Chief Medical OfficerDr. Myers brings extensive executive experience leading the development of clinical programs through US and global regulatory approvalGARDEN CITY, N.Y., March 23, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through i |
Beyond Cancer™ to Present Two Posters for Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2023 AACR Annual MeetingProffered abstracts accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting were released publicly today at 4:30 PM EDTGARDEN CITY, N.Y. and HAMILTON, Bermuda, March 14, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced that Beyond Cancer, Ltd. will present two posters at the upcoming American |
Beyond Air® Announces Participation at Two Upcoming Investor Conferences in March 2023GARDEN CITY, N.Y., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced that St |
XAIR Price Returns
| 1-mo | -7.77% |
| 3-mo | -12.17% |
| 6-mo | -8.56% |
| 1-year | -9.18% |
| 3-year | -21.35% |
| 5-year | 75.02% |
| YTD | -17.72% |
| 2022 | -31.25% |
| 2021 | 79.13% |
| 2020 | 0.76% |
| 2019 | 12.47% |
| 2018 | -6.81% |
Loading social stream, please wait...